Heiko von der Leyen active positions
Companies | Position | Start | End |
---|---|---|---|
ORGENESIS INC. | Chief Tech/Sci/R&D Officer | 31/08/2020 | - |
Career history of Heiko von der Leyen
Former positions of Heiko von der Leyen
Companies | Position | Start | End |
---|---|---|---|
Hannover Clinical Trial Center GmbH | Corporate Officer/Principal | 31/12/2004 | 31/12/2016 |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Chief Tech/Sci/R&D Officer | 31/12/2002 | 31/12/2003 |
Artiss GmbH | Chief Tech/Sci/R&D Officer | 31/12/2000 | 31/12/2001 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Chief Tech/Sci/R&D Officer | 31/12/1997 | 31/12/2000 |
Statistics
International
Germany | 5 |
United States | 2 |
Operational
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ORGENESIS INC. | Health Technology |
Private companies | 4 |
---|---|
Hannover Clinical Trial Center GmbH | |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Artiss GmbH | |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
- Stock Market
- Insiders
- Heiko von der Leyen
- Experience